A947 is a Selective and Efficacious SMARCA2 PROTAC in SMARCA4 Mutant Cancers
2022-12-13
SWI/SNF complex has two important ATP-dependent helicases, SMARCA2 and SMARCA4. In fact, SMARCA2 and SMARCA4 share strong protein sequence homology. But SWI/SNF helicase SMARCA4 is frequently mutated in cancer. The inactivation of SMARCA4 results in a cellular dependence on SMARCA2. Thus, SMARCA2 becomes an attractive synthetic lethal target. Proteolysis targeting chimeras (PROTACs) is an emerging therapeutic modality. PROTACs can induce the degradation of target proteins by recruiting the protein of interest to an E3 ubiquitin ligase. Furthermore, lead the subsequent tagging of the protein to achieve proteasome-mediated destruction through the addition of ubiquitin. The multi-subunit switch/sucrose non-fermentable (SWI/SNF or BAF) complex can facilitate the remodeling of chromatin to regulate key cellular processes including transcriptional regulation and DNA repair.
Keywords
Anticancer | Mutant | NSCLC | PROTACs | SMARCA2



